69.08
-2.33 (-3.26%)
| Previous Close | 71.41 |
| Open | 71.41 |
| Volume | 263,923 |
| Avg. Volume (3M) | 669,590 |
| Market Cap | 2,636,097,280 |
| Price / Book | 3.62 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 4.64% |
| Current Ratio (MRQ) | 37.65 |
| Operating Cash Flow (TTM) | -101.70 M |
| Levered Free Cash Flow (TTM) | -66.74 M |
| Return on Assets (TTM) | -16.25% |
| Return on Equity (TTM) | -23.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Disc Medicine, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.40 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.65% |
| % Held by Institutions | 99.13% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (Cantor Fitzgerald, 80.95%) | Buy |
| Median | 94.00 (36.07%) | |
| Low | 79.00 (Wells Fargo, 14.36%) | Buy |
| Average | 97.50 (41.14%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 65.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 02 Mar 2026 | 79.00 (14.36%) | Buy | 66.54 |
| 17 Feb 2026 | 78.00 (12.91%) | Buy | 65.57 | |
| Truist Securities | 27 Feb 2026 | 83.00 (20.15%) | Buy | 66.62 |
| BMO Capital | 17 Feb 2026 | 100.00 (44.76%) | Buy | 65.57 |
| Cantor Fitzgerald | 17 Feb 2026 | 125.00 (80.95%) | Buy | 65.57 |
| Stifel | 17 Feb 2026 | 110.00 (59.24%) | Buy | 65.57 |
| Wedbush | 17 Feb 2026 | 88.00 (27.39%) | Buy | 65.57 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FRANCHI JEAN M. | - | 69.47 | -6,657 | -468,377 |
| SAVAGE WILLIAM JACOB | - | 68.46 | -5,731 | -392,344 |
| Aggregate Net Quantity | -12,388 | |||
| Aggregate Net Value ($) | -860,722 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 69.13 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FRANCHI JEAN M. | Officer | 14 Apr 2026 | Automatic sell (-) | 6,257 | 70.48 | 440,993 |
| FRANCHI JEAN M. | Officer | 13 Apr 2026 | Automatic sell (-) | 400 | 68.46 | 27,384 |
| SAVAGE WILLIAM JACOB | Officer | 13 Apr 2026 | Automatic sell (-) | 5,731 | 68.46 | 392,344 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |